J. A. Chan

发表

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

Jeffrey W. Clark, C. Earle, J. Meyerhardt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Substrate specificity of alkaline phosphatase from human polymorphonuclear leukocytes.

R. Stinson, A. Gainer, J. A. Chan, 1986, Clinica chimica acta; international journal of clinical chemistry.

SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.

John Garcia, J. Hornick, H. Jacene, 2022, Endocrine-related cancer.

Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study.

Xihong Lin, P. Kraft, D. Christiani, 2016, Endocrine-related cancer.

Reply to A. Koumarianou et al and J. Hadoux et al.

M. H. Kulke, J. A. Chan, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas

N. Raj, P. Munster, L. Fong, 2023, British Journal of Cancer.

Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care

H. Kennecke, Siddharth Singh, L. Fishbein, 2023, Endocrine-related cancer.

Characterization of the Neuroendocrine Tumor Immune Microenvironment

F. Hodi, A. Thorner, F. Hodi, 2018, Pancreas.

Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms

E. Nakakura, E. Mittra, A. Bellizzi, 2023, Endocrine-related cancer.

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline

E. Mittra, A. Bellizzi, A. Gangi, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

Jeffrey W. Clark, C. Earle, J. Meyerhardt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.

J. Meyerhardt, C. Fuchs, L. Kvols, 2013, Endocrine-related cancer.

Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders

Lestat R. Ali, W. Goessling, J. Meyerhardt, 2024, Journal for ImmunoTherapy of Cancer.

Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

Lauren L. Ritterhouse, J. Meyerhardt, D. Rubinson, 2024, Nature communications.

Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis.

J. Berlin, J. Strosberg, A. Dasari, 2023, European journal of cancer.